Treatments for depression including ECT and antidepressants increase brain connectivity in those with clinical depression.
D-Cycloserine, an antibiotic used for the treatment of tuberculosis, increases the effectiveness of transcranial magnetic stimulation for those with major depressive disorder.
Neuroimaging study reveals subtle size differences in the prefrontal region of the brain in young people with major depressive disorders and suicidal behaviors.
The direction of appetite change associated with depression was linked to specific changes in the brain's reward system.
The amygdala-pons connectivity in the pons-corticolimbic network is significantly stronger in patients with major depressive disorder.
Researchers have identified a blood biomarker that predicts the risk of suicide in patients with major depressive disorder. The biomarker also can help researchers understand the molecular changes in suicide victims.
Study reports a significant decline in smoking for those with major depression and substance use disorders, signifying smoking cessation treatments and campaigns are effective in targeting those in groups considered high risk for developing nicotine addiction.
Over 22% of adults who were chronically exposed to parental domestic violence as children developed major depressive disorder later in life. 1 in 6 adults who witnessed PDV developed anxiety disorders, and over 25% later developed substance use disorders.
Researchers identified a link between major depressive disorder and mechanical alterations in blood cells.
People with major depressive disorder who spent more time at home during a two-week period reported more severe symptoms of depression.
Alcohol use disorder is associated with a significant increase in suicidal thoughts in adults.
The antidepressant effect of psilocybin-assisted therapy, in combination with psychotherapy, appears to provide up to a year of symptom relief for some patients with major depressive disorder.
